Effect of Recombinant Activated Factor VII in Critical Bleeding: Clinical Experience of a Single Center

Abstract

Recombinant activated factor VII (rFVIIa) has been successfully used ‘‘off-label’’ in patients with refractory life-threatening hemorrhage. Intravenous rFVIIa was given to 31 patients unresponsive to standard therapy with blood products and surgical reexploration, who were bleeding due to trauma, surgery, organ transplantation, liver cirrhosis, ruptured uterus. We recorded their coagulation and hematologic profiles, acid-base balance, blood loss, number of red blood cells (RBC), plasma and platelet transfusions, complications, and survival. rFVIIa (mean dose 132.2 ± 56.3 μg/kg) effectively contained the hemorrhage in 28/31 (90.3%) cases, with a mean reduction in blood loss from 12.4 ± 10.2 to 2.7 ± 2.2 L (P < .0001). The need for RBC, platelet, and plasma transfusion decreased significantly after rFVIIa, with a consequent significant improvement in clotting of test hematocrit, pH, and bicarbonates. Four patients had adverse events potentially related to rFVIIa. The survival rates after 1 and 30 days were 48.4% and 29.1%, respectively.

Keywords

bleeding FVIIa hemostasis

References

Abshire T. , Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost. 2004;2(6):899-909.

Mariani G. , Lapecorella M. , Dolce A. Steps towards an effective treatment strategy in congenital factor VII deficiency . Semin Hematol. 2006;43(1 suppl 1):S42-S47.

White GC II. Congenital and acquired platelet disorders: current dilemmas and treatment strategies. Semin Hematol. 2006 ;43(1 suppl 1):S37-S41.

Monroe D. , Hoffman M. , Olivier JA , Roberts HR Platelet activity of high-dose factor VIIa is independent of tissue factor . Br J Haematol. 1997;99(3):642-647.

Kenet G. , Walden R. , Elad A. , Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999;354(9193):1879.

Franchini M. , Zaffanello M. , Veneri D. Recombinant factor VIIa. An update on its clinical use. Thromb Haemost. 2005;93(6):1027-1035.

MacLaren R. , Weber LA , Brake H. , Gardner MA , Tanzi M. A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes. Transfusion. 2005;45(9):1434-1442.

Ahonen J. , Jokela R. , Korttila K. An open non-randomized study of recombinant activated factor VII in major postpartum haemorrhage. Acta Anaesthesiol Scand. 2007; 51(7):929-936.

Isbister J. , Philips L. , Dunkey S. , Jankelowitz G. , McNeil J. , Cameron P. Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zeland Haemostasis Register. Intern Med J. 2008;38(3):156-165.

10.

von Heymann C. , Jonas S. , Spies C. , et al. Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta-analysis of published data. Crit Care. 2008;12(1):R14.

11.

Boffard KD , Riou B. , Warren B. , et al, for the NovoSeven Trauma Study Group. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double blind clinical trials. J Trauma. 2005;59(1):8-18.

12.

Rizoli SB , Boffard KD , Riou B. , et al, the NovoSeven Trauma Study Group. Recombinant activated factor VII as adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials. Crit Care. 2006;10(6):R178.

13.

Mayer SA , Brun NC , Begtrup KB , et al. Recombinant activated factor VII for acute intracerebral hemorrhage . N Engl J Med. 2005;352(8):777-785.

14.

Bosch J. , Thabut D. , Bendtsen F. , et al, the European Study Group on rFVIIa in UGI Haemorrhage. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology. 2004;127(4):1123-1130.

15.

Pihusch M. , Bacigalupo A. , Szer J. , et al. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost. 2005;3(9):1935-1944.

16.

Diprose P. , Herbertson MJ , O’Shaughnessy D. , Gill RS Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth. 2005;95(5): 596-602.

17.

Chuansumrit A. , Wangruangsatid S. , Lektrakul Y. , Chua MN , Zeta Capeding MR , Bech OM the Dengue Study Group. Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study. Blood Coagul Fibrinolysis . 2005;16(8):549-555.

18.

Stanworth SJ , Birchall J. , Doree CJ , Hyde C. Recombinant factor VIIa for the prevention and treatment of patients without haemophilia. Cochrane Database Syst Rev. 20072):CD005011.

19.

Johansson PI Off-label use of recombinant factor VIIa for treatment of haemorrhage: results from randomized clinical trials. Vox Sang. 2008;95(1):1-7.

20.

Ranucci M. , Isgrò G. , Soro G. , Conti D. , De Toffol B. Efficacy and safety of recombinant activated factor VII in major surgical procedures: systematic review and meta-analysis of randomized clinical trials . Arch Surg. 2008;143(3):296-304.

21.

Mayer SA , Brun NC , Begtrup K. , et al. Fast trial investigators. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358(20):2127-2137.

22.

Spahn DR , Rossaint R. Coagulopathy and blood component transfusion in trauma. Br J Anaesth. 2005;95(2): 130-139.

23.

Lynn M. , Jeroukhimov I. , Klein Y. , Martinowitz U. Update in the management of severe coagulopathy in trauma patients. Intensive Care Med. 2002;28(suppl 2): S241-S247.

24.

Levy JH Massive transfusion coagulopathy. Semin Hematol. 2006;43(1 suppl 1):S59-S63.

25.

Mallarkey G. , Brighton T. , Thomson A. , Kaye K. , Seale P. , Gazarian M. An evaluation of eptacog alfa in nonhaemophiliac conditions. Drugs. 2008;68(12):1665-1689.

26.

Martinowitz U. , Michaelson M. for the Israeli Multidisciplinary rFVIIa Task Force. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost. 2005;3(4):640-648.

27.

Karkouti K. , Beattie WS , Crowther MA , et al. The role of recombinant factor VIIa in on-pump cardiac surgery: proceedings of the Canadian Consensus Conference . Can J Anaesth. 2007;54(7):573-582.

28.

Vincent JL , Rossaint R. , Riou B. , Ozier Y. , Zideman D. , Spahn DR Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding-an European perspective. Crit Care. 2006;10(4):R120.

29.

Welsh A. , McLintock C. , Gatt S. , Somerset D. , Popham P. , Ogle R. Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage. Aust N Z J Obstet Gynaecol. 2008 ;48(1):12-16.

30.

Bishop CV , Renwick WE , Hogan C. , Heusler M. , Tuckfield A. , Tatoulis J. Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery. Ann Thorac Surg. 2006;81(3):875-879.

31.

Wolfang C.

Acidosis and impaired blood coagulation: what and how to correct before using recombinant factor VIIa

Crit Care Med. 2007 ;35(6):1627-1628.

32.

Hoffman M. Laboratory monitoring of high-dose factor VIIa therapy. Ann Intern Med. 2003;139(9):791.

33.

Kaplan JL , Frangos S. Clinical review: acid-base abnormalities in the intensive care unit. Crit Care. 2005;9(2):198-203.

34.

Meng ZH , Wolberg AS , Monroe DM III , Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients . J Trauma. 2003;55(5):886-891.

35.

Aledort LM Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost. 2004;2(10):1700-1708.

36.

O’Connell KA , Wood J. , Wise RP , Lozier JN , Braun M. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006; 295(3):293-298.

37.

Mayer SA for the FAST Trial Steering Committee. Complications in patients with intracerebral hemorrhage treated with recombinant factor VIIa. Neurology. 2007;69(3):319-320.